The abstract is read at the publisher; the summary is JClub's.
Higher anti-HPV16 antibody levels in Rwandan women are linked to lower anogenital HPV16/18 prevalence, with the strongest effect in the highest antibody quartile (aOR=0.23).
- Why it matters: Protection against anogenital high-risk HPV in women with HIV is uncertain, even though quadrivalent HPV vaccination has shown population-level benefits for cervical cancer.
- What they did: Among 3,058 Rwandan women (with and without HIV) recruited into four birth-era sub-cohorts after Rwanda’s 2011 quadrivalent HPV introduction, investigators measured anti-HPV16 antibodies and tested vaginal and anal specimens for HPV16/18.
- The result: Anogenital HPV16/18 prevalence fell from 11.0% to 2.5% across the lowest to highest anti-HPV16 antibody quartiles (ptrend<0.001), and the highest quartile showed reduced odds in both women without HIV (aOR=0.24) and women with HIV (aOR=0.23).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.